---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-227059"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2026-05-15T20:46:48+00:00"
generated_at: "2026-05-15T20:52:04.741363+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics holds annual meeting post 1-for-25 reverse split; all proposals pass

## Summary
- All six directors elected; votes for ranged from 11.9M to 12.4M; broker non-votes ~50.8M.
- Ratification of CBIZ CPAs as auditor for 2026 approved with 60.9M in favor.
- Advisory say-on-pay approved with 10.4M for, 3.4M against.
- Sixth amendment to 2020 Stock Incentive Plan approved (7.98M for, 5.65M against).
- Meeting held after 1-for-25 reverse split effective April 2, 2026; vote results on pre-split share count.

## SEC filing metadata
- accession: 0001193125-26-227059
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2026-05-15T20:46:48+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000119312526227059/0001193125-26-227059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000119312526227059/pstv-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-227059
- JSON: https://secwatch.observer/filing/0001193125-26-227059.json
- Plain text: https://secwatch.observer/filing/0001193125-26-227059.txt

## Key facts
- Shareholder Votes
  PLUS THERAPEUTICS, INC. shareholders approved Sixth Amendment and Restatement of the Company’s 2020 Stock Incentive Plan at the 2026-05-14 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-05-14
  source text: Proposal No. 4 – Sixth Amendment and Restatement of the Company’s 2020 Stock Incentive Plan. The Company’s stockholders approved the sixth amendment and restatement of the Company’s 2020 Stock Incentive Plan. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 7,976,002 5,648,887 425,414 50,807,018
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526227059/0001193125-26-227059-index.htm
- Shareholder Votes
  PLUS THERAPEUTICS, INC. shareholders approved Advisory Vote on the Compensation of Named Executive Officers at the 2026-05-14 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-05-14
  source text: Proposal No. 3 - Advisory Vote on the Compensation of Named Executive Officers. The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 10,389,498 3,364,694 296,111 50,807,018
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526227059/0001193125-26-227059-index.htm
- Shareholder Votes
  PLUS THERAPEUTICS, INC. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-05-14 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-05-14
  source text: Proposal No. 2 - Ratification of Appointment of Independent Registered Public Accounting Firm. The Company’s stockholders ratified the appointment of CBIZ CPAs, P.C. as the Company’s independent registered public accounting firm for the 2026 fiscal year. The votes regarding this proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 60,860,051 2,292,062 1,705,208 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526227059/0001193125-26-227059-index.htm
- Shareholder Votes
  PLUS THERAPEUTICS, INC. shareholders approved Election of Directors at the 2026-05-14 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-05-14
  source text: Proposal No. 1 - Election of Directors. The Company's stockholders elected the following persons, who were listed in the Proxy Statement, to the Board of Directors of the Company (the “Board”) to hold office for a term expiring at the Company’s Annual Meeting of Stockholders in 2027 and until each such person’s successors is duly elected and qualified, or until his or her earlier death, resignation or removal: Votes For Votes Withheld Broker Non-Votes Howard Clowes 11,863,579 2,186,724 50,807,018 An van Es-Johansson, M.D. 12,384,866 1,665,437 50,807,018 Richard J. Hawkins 12,344,152 1,706,151 50,807,018 Marc H. Hedrick, M.D. 12,350,511 1,699,792 50,807,018 Ronald A. Andrews 12,417,138 1,633,165 50,807,018 Kyle Guse, Esq., MBA, CPA 12,384,591 1,665,712 50,807,018
  evidence_url: https://www.sec.gov/Archives/edgar/data/1095981/000119312526227059/0001193125-26-227059-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.